

Fundamental dimension Equity attribute | AMFCPeer $42.00▲+2.44% Cap $37.69MP/E 9.9x QuantScore62/100 | CBAFPeer $46.390.00% Cap $69.93MP/E 10.6x QuantScore66/100 | CTYPLeader $10.800.00% Cap $24.41MP/E 9.7x QuantScore69/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
73/100 |
59/100 |
95/100 |
Valuation Multiples, PEG & DCF upside | 85/100 | 100/100 | 78/100 |
Health Piotroski, Altman Z, leverage & liquidity | 30/100 | 30/100 | 20/100 |
Growth Revenue / earnings growth & margins | 62/100 | 74/100 | 82/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | 9.9x | 10.6x | 9.7x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | 6.9x | 8.3x | 4.2x |
Price / Sales | 1.6x | 1.9x | 1.1x |
Price / Free Cash Flow | 9.0x | — | 8.3x |
PEG ratio | 0.33 | 0.49 | 2.24 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 5 / 9 | 5 / 9 | 2 / 9 |
Altman Z-Score | 0.31 (Distress) | 0.31 (Distress) | 0.48 (Distress) |
Total debt / equity | 0.09 | 0.00 | 0.08 |
Quick ratio | — | — | 0.0x |
Interest coverage | 0.6x | 0.7x | 0.4x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | +7.3% | +14.3% | +77.6% |
Net income growth YoY | +39.1% | +81.0% | +52.8% |
Gross margin (TTM) | 61.9% | 71.4% | 64.3% |
Operating margin (FY) | 19.4% | 21.0% | 13.7% |
FCF margin (FY) | 16.4% | 17.8% | 13.6% |
5. Trailing price performancePrice change over period |
1M return | +10.5% | +1.6% | 0.0% |
3M return | +22.6% | +19.7% | +7.2% |
6M return | +24.8% | +17.1% | +35.0% |
Year to date | +38.2% | +22.9% | +35.8% |
1Y return | +44.8% | +52.1% | +72.8% |
3Y return | +120.8% | +149.4% | +66.2% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $32.17 -23.4% premium | $145.44 +213.5% upside | $10.69 -1.1% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |